Leerink analyst David Risinger notes that Pfizer (PFE) disclosed on December 9, 2025, that it entered into an exclusive global collaboration and license agreement with Fosun Pharma’s subsidiary YaoPharma for YP05002, a Phase 1 small-molecule GLP-1RA. The firm understands that this drug candidate’s chemical scaffold is similar to Eli Lilly’s (LLY) orforglipron rather than danuglipron. The ongoing Phase 1 is enrolling 76 patients in Australia, with an estimated primary completion date of Apr 2026. Based on the trial info page, YP05002 is dosed daily, and Phase 1 includes three multiple ascending dose cohorts. Pfizer plans to combine YP05002 with its internal GIPR antagonist, Leerink adds. The firm says it awaits future updates on YP05002. Leerink has a Market Perform rating on Pfizer.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- Pfizer signs exclusive collaboration and license agreement with YaoPharma
- Mixed options sentiment in Pfizer with shares up 0.13%
- Can Life Wave Sciences Disrupt the Obesity Market? WVE Soars 147% after Initial Results
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List